Results 161 to 170 of about 365,877 (337)

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects

International Journal of Cancer, EarlyView.
What's New? Venous thromboembolism (VTE) is common in cancer patients, with direct oral anticoagulants, including rivaroxaban, recommended as first‐line therapy. However, oral anticoagulant use is limited due to the growing use of targeted therapy and concerns about drug‐drug interactions.
Esther M. Hollander, Alessandra I. G. Buma, Jenneke Leentjens, Paddy K. C. Janssen, Michel M. van den Heuvel, David M. Burger, Berber Piet, Rob ter Heine   +7 more
wiley   +1 more source

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

International Journal of Cancer, EarlyView.
What's New? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, Tali Voloshin, Lilach Koren, Bella Koltun, Cfir David, Kerem Wainer‐Katsir, Avital Vorontsova, Boris Brant, Simona Zisman‐Rozen, Hila M. Ene, Roni Frechtel‐Gerzi, Shay Cahal, Anat Klein‐Goldberg, Lena Lifshitz, Efrat Zemer Tov, Mai Shai, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti   +21 more
wiley   +1 more source

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

Cancer Management and Research, 2019
Ruxu You,1,* Jinyu Liu,2,* David Bin-Chia Wu,3 XinYu Qian,4 Boxiang Lyu,5 Yu Zhang,1 Nan Luo4 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China ...
You R, Liu J, Wu DBC, Qian X, Lyu B, Zhang Y, Luo N   +6 more
doaj  

Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC [PDF]

, 2018
Francesco Gelsomino, Giancarlo Facchini, Maria Aurelia Barbera, Giuseppe Lamberti, Stefano Brocchi, Giuseppe Rossi, Andrea Ardizzoni   +6 more
openalex   +1 more source

Tumor‐educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation

International Journal of Cancer, EarlyView.
Abstract Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome ...
Whi‐An Kwon, Min‐Kyung Lee, Eunyong Ahn, Heeyeon Kim, Yong Sang Song, Taejin Ahn   +5 more
wiley   +1 more source

Coronavirus disease 2019 infection reduces EGFR‐TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

International Journal of Cancer, EarlyView.
What's New? Lung cancer patients with COVID‐19 experience significantly increased risk for severe illness and mortality. However, research addressing the effect of COVID‐19 on non‐small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) remains unknown.
Wenjie Tang, Xiaoxuan Hou, Li Li, Hanxi Zhao, Xiaoyong Tang, Wanqi Zhu, Xiaohui Yan, Jing Liu, Qian Wu, Zhu Qiao, Shanliang Hu, Mingwei Zhang, Xiaolin Li, Peng Xie   +13 more
wiley   +1 more source

P1.15-16 ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network [PDF]

, 2018
Huimin Lin, Xiaoyun Pan, Hui Huang, Giulia Salvatore, Stephen Clarke, Howard West   +5 more
openalex   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source

EP1.14-43 The Safety of First-line and Subsequent Monotherapy of PD-1/PD-L1 Inhibitors in NSCLC: A Meta Analysis [PDF]

, 2019
Yinfeng Yang, Zhilan Xie, Peter S. Pang, Na Wang, Huiying Liang, Lei Zhao   +5 more
openalex   +1 more source

A Pan‐Cancer Microenvironment Atlas Constructed by DECEPTICONx

iMetaMed, EarlyView.
DECEPTICONx builds the most comprehensive pan‐cancer TME atlas to date from > 11,000 TCGA samples using 535,665 single cells, revealing 102 immune/stromal subtypes with robust novel associations to patient outcomes, immunotherapy response, and intercellular coordination in the TME.
Yida Gu, Fulan Deng, Lianchong Gao, Zhiyu Chen, Jianping Chen, Jiale Wu, Zengqiang Xia, Zhijian Li, Fangkaikai Cheng, Jie Chen, Henry H. Y. Tong, Wantao Chen, Xiaoqing Pan, Xin Zou, Jie Hao   +14 more
wiley   +1 more source